Cécile Pages
Cécile Pages is an expert in Dermatology at Oncopole Claudius Regaud (France). Cécile Pages has authored 187 publications, the most recent in 2025, and is an investigator in 6 clinical trials, 2 of them ongoing. SLR score: 450 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1999 - 2025
Number : 187
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Update on dermatological toxicities of immune checkpoint inhibitors. PMID 41285238 — skin, omalizumab, vitiligo, neoplasms, pemphigoid, bullous, immune checkpoint inhibitors, pruritus, therapeutics, psoriasis, general surgery, dermatology | Presse Med | 2025 | 0 |
| Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. PMID 40993242 — cells, safety, molecular biology, melanoma, neoplasms, immune checkpoint inhibitors, nivolumab, antibodies, monoclonal, therapeutics, ipilimumab | Nat Med Top journal | 2025 | 0 |
| Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL). PMID 40658732 — syphilis, melanoma, drug-related side effects and adverse reactions, immune checkpoint inhibitors, therapeutics, dermatology | Br J Dermatol | 2025 | 3 |
| [Atypical and/or systemic dermatologic disorders related to immune checkpoint inhibitors: A review]. PMID 39580255 — internal medicine, immune checkpoint inhibitors, therapeutics | Rev Med Interne | 2024 | 1 |
| TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study. PMID 40098565 — cells, melanoma, neoplasms, immune checkpoint inhibitors, nivolumab, therapeutics, memory, plasma, non-responder | Int J Cancer | 2025 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of Subcutaneous Nivolumab Relatlimab Fixed dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma NCT05625399 — melanoma, nivolumab | Phase 3 | Active not recruiting | 2023 |
| Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma NCT05429138 — fertility, blood, melanoma, ovary, ovarian reserve, aftercare, aged, therapeutics, men | N/A | Recruiting | 2022 |
LeadR Networks
Main global connection map